Zydus Cadila has received the final approval from the USFDA to market Colesevelam Hydrochloride Tablets, (US RLD – Welchol), 625 mg. This medication is used along with a proper diet and exercise, to lower cholesterol in people with high levels of cholesterol in the blood. Lowering cholesterol decreases the risk of heart disease and helps prevent strokes and heart attacks. It will be manufactured at the group’s formulations manufacturing facility at SEZ, Ahmedabad.
The group now has 273 approvals and has so far filed over 360 ANDAs since the commencement of the filing process in FY 2003-04.
Shares of CADILA HEALTHCARE LTD. was last trading in BSE at Rs.228.2 as compared to the previous close of Rs. 232.2. The total number of shares traded during the day was 59385 in over 1230 trades.
The stock hit an intraday high of Rs. 231.65 and intraday low of 224.3. The net turnover during the day was Rs. 13503164. – Equity Bulls